Drug intelligence / Profile preview

CanQuit

Development stage: Preclinical
Lead developer: Incannex Healthcare
Modality: Small Molecules
Administration: Oral, Buccal, Sublingual

Overview

CanQuit is a cannabinoid-based therapeutic drug candidate initially developed by APIRx Pharmaceuticals USA and later acquired by Incannex Healthcare. It is designed to target addiction and is delivered via a patented medicated chewing gum technology. CanQuit is part of a broader portfolio of cannabinoid-based assets aimed at various conditions, leveraging Incannex's development capabilities and APIRx's extensive intellectual property in cannabinoid medicine.

Targets

CHRNA7 (α7 nicotinic receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on CanQuit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CanQuit.

Explore the full profile